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The effect of aortic baroreceptor stimulation on blood pressure manipulation was
assessed using the goat species Capra aegagrus hircus. The aim of this study was to
manipulate blood pressure with future intention to treat high blood pressure in humans.
The ages of the animals ranged from 6 months to 2 years. A standard anesthesia
protocol was used. A lateral thoracotomy was performed to gain access to the aortic
arch. Data was collected with the Vigileo system. Pre stimulation blood pressure was
compared with maximum post stimulation blood pressure values. Results were analyzed
with the Wilcoxon signed rank test. In the study 38 animals were enrolled. Baroreceptor
stimulation was performed for each animal using 3 different electrodes each of which
emits an electrical impulse. In the pilot phase of the study, the median baseline blood
pressure prior to stimulation of the baroreceptors was 110.8 mmHg. After stimulation the
median blood pressure decreased to 88 mmHg. The average decrease in blood pressure
was 22.8 mmHg. This decrease of blood pressure after stimulation of the baroreceptors
is statistically significant (p < 0.0001) and the proof of concept was shown. During the
extended phase all three probes had a significant effect on blood pressure lowering (p <
0.0001). The study confirmed that aortic baroreceptor stimulation has an effect on blood
pressure lowering. This is a novel field of blood pressure manipulation. The hemodynamic
effects of long-term aortic baroreceptor stimulation are unknown. Further investigations
need to be done to determine whether a similar effect can be induced in different species
such as primates and humans.
Keywords: aortic baroreceptor stimulation, autonomic nervous system, carotid baroreceptors, hypertension,
systolic blood pressure
INTRODUCTION
Arterial hypertension in humans is the most important risk factor for cardiovascular disease,
premature death, and disability globally (1). Despite the effect of potent pharmacological drugs in
treating blood pressure, a substantial number of patients do not achieve goal blood pressure values.
The cardiovascular diseases include coronary heart disease, stroke, heart failure, and arrhythmias
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(such as atrial fibrillation) (2–4). Various drug trials and life-style
change studies showed significant reductions in cardiovascular
events, yet globally hypertension remains poorly controlled, with
less than a third of patients achieving target blood pressure
(1, 5). Data from the National Health and Nutrition Examination
Survey (NHANES 2013–2014) also demonstrated an increased
incidence of hypertension (6). These observations led to the
search for alternative measures for blood pressure control such
as surgical intervention by implanting an aortic baroreceptor
stimulation device.
In 2015 it was estimated that the global prevalence of
hypertension is 1.13 billion worldwide and that 150 million
patients in Europe suffer from hypertension. The estimated
increase of people with hypertension by 2025 is to be a number
of 1.5 billion (7). The financial burden on the health care system
in direct and indirect cost in the United States of America
in 2008 was $50 billion and impacted more than 76 million
Americans (8).
An increased activity of the sympathetic nervous system,
in part regulated by afferent input arising from arterial and
cardiopulmonary baroreceptors, has been demonstrated to play
a critical role in developing and sustaining hypertension (9).
Activation of these receptors causes inhibition of the sympathetic
system and potentially can reduce blood pressure.
Recently, electrical stimulation of the carotid sinus showed
encouraging results in lowering blood pressure and reducing
sympathetic drive. This was achieved both in short-term and
long-term period of over 5 years and may have the potential to
become a novel therapy for hypertension (10).
A variety of causes can lead to hyper-activity of the
sympathetic nervous system - one such cause is inactive
baroreceptors. Low-pressure baroreceptors have an effect on
renal-endocrine and circulatory systems effecting retention of
salt and water. In addition, the neuro hormonal system resets
the baroreceptor set point over time and this baroreceptor
dysfunction consequently leads to an increase in blood
pressure (11).
Baroreceptors are located in blood vessels of all vertebrate
animals. The sensory nerve endings of arterial baroreceptors are
simple sprayed endings that lie in the adventitia of an artery.
These baroreceptors function as a type of mechanoreceptor
sensory system. Increase in the arterial pressure and thus
stretching of the artery, results in action potentials triggered
in these baroreceptor endings. Baroreceptors provoke action
potentials with each heartbeat. These action potentials cause
neuron stimulation which is conducted to the central nervous
system mainly via the autonomic nervous system (8, 12).
This neuron stimulation modulates the heart rate, inotropic
activity, thus also cardiac output as well as vascular tone in the
form of peripheral resistance (8).
The release of hormones, such as adrenaline, that targets
cardiac function, can affect these baroreceptors instantly via
sympathetic pathways. Baroreceptors respond immediately to
maintain a stable blood pressure. Mean arterial pressure (MAP)
and pulse pressure influence nerve firing so that the autonomic
nerve system maintains near to the normal range of MAP.
Physiological changes in the set point of blood pressure control
occur in physical activity, hypertension, and heart failure (9, 12–
14). Adjustment over time occurs in this system, which alters the
sensitivity of these receptors. Changes in the set point explain
why elevated blood pressure is maintained during exercise and
in patients with chronic hypertension (15).
Previous investigators have evaluated the effect of carotid
baroreceptor stimulation on hypertension (16). New areas
investigated in baroreceptor activity included hypertension
treatment (carotid stimulation), sleep apnoea syndrome, and
even diabetes control. This needs to be investigated further (10,
17). During these investigations it was found that diabetes control
and sleep apnoea improved.
Carotid baroreceptor stimulation has already been evaluated
in a double blind randomized placebo controlled Rheos Pivotal
Trial in 2012 by Bakris. These results showed significant benefit
for endpoints of sustained efficacy (18).
The Barostim neo trial showed that a second-generation,
minimally invasive system for baroreflex activation therapy
(BAT) led to a significant reduction in SBP. It was then stated
that this therapy is the only treatment that demonstrated long-
term safety and efficacy in a large-scale double blind, randomized
control trial for the treatment of resistant hypertension (8, 10).
In 2012 Bloch et al. showed that there is controversy regarding
the procedural safety of the device and the implantation
procedure (19).
BAT therapy is intensely evaluated in resistant hypertension
with excellent results in lowering blood pressure. The Reos
Biostim system was developed for the treatment of resistant
hypertension. Further studies of BAT investigated the long-term
effect of this modality on heart failure with reduced ejection
fraction (20–22). A further study on the effects of chronic carotid
baroreceptor activation on arterial stiffness in severe heart failure
was published in 2016 (23).
The rationale for using aortic arch baroreceptor stimulation
in this study is based on a study that was done on the sensitivity
between aortic baroreceptors and carotid baroreceptors
indicating that the aortic depressor neurons possessed a higher
percentage of mechano-sensitive neurons (24). Therefore, we
postulate that aortic baroreceptor stimulation may be more
effective in lowering blood pressure.
Stimulation of the aortic arch baroreceptors has not been
previously investigated. This research study aimed to investigate
a novel mechanism in blood pressure manipulation through
aortic arch baroreceptor stimulation with the hypothesis that
stimulation of aortic arch baroreceptors will cause a significant
reduction in systolic blood pressure (SBP).
MATERIALS AND METHODS
Study Design
The study was designed as a proof of concept. It was approved by
the University of Pretoria Biomedical Research Council (Project
noH007/14). Initially, during the pilot study, a total of 21 animals
were subjected to aortic baroreceptor stimulation and the blood
pressure response was measured. During the extension of the
study the efficacy of blood pressure lowering was evaluated with
three different probes in 38 experimental animals of the goat
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species Capra aegagrus hircus. This species was chosen due to the
convenient size, especially of the aortic arch and consequently the
ease to identify the sites of the aortic baroreceptors. Both sexes
were included in this study. The age of the animals varied from 6
months to 2 years.
Anesthetic Protocol
All research animals received general anesthesia. The anesthetic
induction and procedure included a single bolus of Alfaxalone
(5 mg/kg) combined with intramuscular Midazolam (0.5 mg/Kg)
via a jab stick. This was followed by intubation through
which Isoflurane and oxygen were delivered. Maintenance fluid
(Lactated Ringers solution) was administered via an auricular
vein at 10ml/kg with a Braun infusion pump.
The femoral artery catheter was connected to the Vigileo
system that measured blood pressure intra-arterially. After
five stable blood pressure measurements at 5min intervals,
baroreceptor stimulation was initiated. The duration of
stimulation varied between animals and was continued until the
lowest SBP was observed. The duration of stimulation ranged
from 15 to 45min. Stimulation was applied until maximum SBP
was achieved. The protocol did not include a recovery phase.
Subsequent measurements were taken at 5min intervals until
the lowest blood pressure value was recorded. All animals
were euthanized after the intervention according to protocol
requirements.
Surgical Procedures
This procedure consisted of left lateral intercostal thoracotomy
incision at the level of the 3rd and 4th ribs. A bolus of
Buprenorphine (0.02 mg/kg IV) was administered prior to the
surgical procedure to minimize the effect of pain on SBP.
Subsequently, the aortic arch was dissected down to the adventitia
layer. The probe was then placed on the outer surface of the
aortic arch at the level of bifocation of the aorta into dorsal and
FIGURE 1 | Stimulation results- Octad probe (pilot phase). Results of pre and
post stimulation for each research animal are plotted in this figure (n = 21).
These are the results of aortic arch baroreceptor stimulation with the Octad
experimental probe. SBP blood pressure values are represented in mmHg.
ventral vessels. This is the usual anatomical location of the aortic
baroreceptor in goats. The position of the probe was confirmed
by direct visual inspection.
Adverse Events
Adverse events that were monitored included major bleeding
during the surgical exposition and during the stimulation phase.
One major bleeding occurred due to aortic perforation. Blood
pressure drop during the initiation phase of anesthesia of the
animals was monitored as was provided by the anesthesia
protocol.
Probe Design
The Octad probe is designed as an eight contact probe, bended
to fit over the aorta. The eight contacts provide optimum contact
area to cover the baroreceptors on the aortic wall. This consists of
probe length of 44.5mm, inter-electro spacing of 6mm, electrode
size of 2.4 x 3.8mm and electro design of 2 rows of 4 electrodes
staggered.
The Quad probe is designed with four contact areas. The
probe length is 44mm with inter electrode spacing of 5mm,
electrode size of 2 × 2mm and inline design of one row of 4
contacts.
The Pace probe is designed as a single tip stimulation probe
with a tip size of 1 mm2.
FIGURE 2 | The box plot for the results of systolic blood pressure lowering in
the pilot phase using the Octad probe. The results of the distribution of the
median are shown in the figure, together with the p-value after applying the
Wilcoxin rank test. Systolic blood pressure values are represented in mmHg.
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FIGURE 3 | Effects of aortic baroreceptor stimulation on diastolic blood
pressure. The results of the distribution of the median are shown in the figure,
together with the p-value after applying the Wilcoxin rank test. Diastolic blood
pressure values are represented in mmHg.
Stimulation Procedure
Stimulation of the aortic arch was performed using the Octad,
Quad and Pace probes at a voltage and frequency of 10 mvolts
and 60 Hertz, respectively.
Data was collected using the Vigileo System (Edwards
Lifesciences, Irvine, California, United States) which is a
hemodynamic monitoring system that allows monitoring of
blood pressure and pulse rate. This system was connected to a
femoral artery cannulation probe. Blood pressure response was
measured via the arterial pressure wave of the femoral artery.
Blood pressure measurements were recorded at 5min intervals
in order to determine the effect of aortic baroreceptor stimulation
on blood pressure and pulse rate.
Ethical Approval
These processes were done after best practice methods had been
approved by the ethics committee of UPBRC (University of
Pretoria Animal Ethics Committee registration with the National
Health Research Ethics Council: AREC-261110-001). UPBRC
facility registration number with the South African Veterinary
Council: FR15/1383.
Primary Endpoints
The primary end-point was the maximum reduction in SBP
that could be achieved with baroreceptor stimulation (proof of
concept). In the extension phase of the study the endpoint was
to evaluate the effect of three different probe designs on SBP
lowering.
FIGURE 4 | Effects of baroreceptor stimulation on mean arterial pressure. The
results of the distribution of the median are shown in the figure, together with
the p-value after applying the Wilcoxin rank test. Mean arterial pressure values
are represented in mmHg.
Statistical Analysis
As per trial design assumptions, sample size was calculated to
adequately power endpoint results for a power of 90% at the
significance level of 0.05. Sample size was determined as 17
experimental animals. Twenty one animals were included in
the study. The first four animals were used to determine the
technical aspects. These four animals were included in the final
data analysis.
For this research the null hypothesis of no relationship
between stimulation of aortic baroreceptors and a reduction in
blood pressure was applied. By rejecting the null hypothesis
would then conclude that there are grounds for believing that
there is a relationship between stimulation of the receptors and
the lowering of blood pressure. The null hypothesis was rejected
if a significant blood pressure lowering, defined as a 20 mmHg
decrease in blood pressure, was achieved. The control measure
is defined as the blood pressure reading before stimulation of
the receptors. The effect is measured by applying the relevant
statistical tests as described below.
A significant reduction in SBP of 20 mmHg (due to
stimulation) sample size determination was applied. A standard
deviation of 23.62 mmHg is assumed (
√
2∗ expected range for
reduction in SBP/∂ = √2 ∗ 100/∂). A sample size of 17 animals
had 90% power to detect a change from baseline of at least 20
mmHg when the standard deviation is 23.62 mmHg and testing
is two-sided at the 0.05 level of significance. During this study
baseline and endpoint blood pressure results were compared.
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FIGURE 5 | Effects of baroreceptor stimulation on pulse rate. The results of
the distribution of the median are shown in the figure, together with the p-value
after applying the Wilcoxin rank test. Pulse rate values are presented in beats
per minute.
FIGURE 6 | Pre- and Post- stimulating SBP for three different stimulation
probes. This figure shows the systolic blood pressure lowering for the Octad,
Quad, and Pace probes. With all three stimulation probes a highly significant
lowering in blood pressure was achieved with a p-value = 0.0001.
The final results were analyzed with the Kolmogorov-Smirnov
test that showed that both pre-stimulation and post-stimulation
data were non-parametric. The Wilcoxin Signed-Rank Test (SAS
Version 9.4) was therefore applied to achieve the final results.
Statistical analysis of the study was done by the Statistical
Department at the University of Pretoria.
FIGURE 7 | Systolic blood pressure lowering for three different stimulation
probes. This figure shows the systolic blood pressure lowering for the Octad,
Quad, and Pace probes. There is superiority of the Octad probe in lowering
blood pressure (p-value = 0.001).
With further analysis the Friedman (compare=pairwise) test
was applied to show the differences between the three probes.
Three probes were used and allocated according to a numeric
randomized design. Pre- and post- stimulation readings were
collected manually for each probe.
RESULTS
During the pilot phase and as proof on concept 21 animals
were used. The initial four animals were allocated to perfect the
technique. Ultimately, the variance was so low that the data from
these four animals were added to the final data as per protocol.
The baseline SBP before stimulation had a median value
of 110.8 mmHg with a standard deviation from the mean of
13.67 mmHg. After stimulation, SBP was 88 mmHg with a
standard deviation of 15.93 mmHg from the mean. This showed
a significant lowering of SBP with a median reduction of 22.8
mmHg. Pre- and post-stimulation values for each animal are
shown in Figure 1. The box plot for the results of SBP lowering in
the pilot phase is shown in Figure 2. The Octad probe was used
during the pilot phase.
The effects of aortic baroreceptor stimulation on diastolic
blood pressure (DBP) are shown in Figure 3. The pre-stimulation
value of DBP had a median of 90.0 mmHg with a standard
deviation from the mean of 15.1 mmHg. The DBP post-
stimulation was had a median of 16 mmHg with a standard
deviation from the mean of 17.25 mmHg.
The MAP pre- and post-stimulation is shown in Figure 4.
The median value pre-stimulation was 96.7 mmHg and post-
stimulation was 71.3 mmHg with a standard deviation from the
mean of 14 and 15.94, respectively.
Pulse rate also changed during baroreceptor stimulation and
the pre- and post-stimulation results are shown in Figure 5. The
pre-stimulation value of the pulse rate was a median of 99.0 beats
per minute (bpm) with a standard deviation from the mean of
14.5. The post-stimulation value of the pulse rate was a median
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of 70 bpm and the standard deviation of 20 bpm which indicates
a lowering of pulse rate after stimulation.
In the extension phase of the study three probes (Octad, Quad
and Pace) were used to evaluate whether a different probe design
would have a similar effect on blood pressure lowering.
Data for the different probes were non-parametric with the
skewness coefficients of 0.8 (probe O) 0.18 (probe Q) and 4.5
(probe P), respectively. The distribution of the pre- and post-
stimulating SBP for the 3 probes is presented in Figure 6. For the
Octad probe the median blood pressure before stimulation was
110.8 mmHg (standard deviation of 13.62) and the median blood
pressure lowering after stimulation was 22.8 mmHg (standard
deviation= 10.9).
For the Quad probe the median blood pressure before
stimulation was 108.2 mmHg (standard deviation = 13.14) and
after stimulation the blood pressure lowering had a median value
of 12.2 mmHg (standard deviation= 11.5).
For the Pace probe the pre-stimulation median blood pressure
was 104.7 mmHg (standard deviation = 37.1). After stimulation
the median lowering value was 12.4 mmHg (standard deviation
15.48).
With all three stimulation probes, despite the difference in
design, a highly significant lowering in blood pressure was
achieved with a p = 0.0001 according to the Wilcoxin Signed-
Rank test. The null hypothesis was thus rejected and aortic
baroreceptor stimulation is associated with lowering in blood
pressure.
With further analysis on the differences between the three
probes, it was proved that the Octad probe was most effective
when compared to the other two probes in lowering SBP with
p-value of 0.001. This result is shown in Figure 7.
DISCUSSION
The findings of the current study suggest that stimulation
of aortic baroreceptors in an animal model may represent a
viable method to decrease arterial pressure. Stimulation of aortic
baroreceptors induced a significant decrease in systolic, diastolic,
and mean arterial pressure in this animal model.
Hypertension in humans is an important cause of morbidity
and mortality worldwide and significant resources are utilized
annually to treat hypertension, (1). However, compliance with
pharmacological therapy is relatively poor and few patients
achieve target blood pressure (25, 26). Furthermore, the side
effects of medication contribute to poor compliance and some
patients with resistant hypertension require multiple agents (25,
27–29).
Aortic baroreceptor stimulation caused a significant decrease
in SBP in all animals tested. Importantly, the median decrement
in SBP observed in this study was highly significant with a
magnitude of 22.8 mmHg and was sustained for the duration of
the procedure with one serious adverse effect only in the form of
aortic perforation with the Pace-probe. The tip design of the Pace
probe might have caused this complication. General anesthesia
and appropriate analgesics were administered to the animals
to minimize sympathetic stimulation during the procedure.
The blood pressure response to baroreceptor stimulation was
carefully monitored to ensure the accuracy of all measurements
taken.
All three probes caused significant reduction in SBP with
median decrements of 22.8, 12.2, and 12.4 mmHg for the Octad,
Quad, and Pace probes, respectively. The Octad probe was most
effective when compared to the other two probes. This may be
attributed to an increased surface area of the Octad probe which
has 8 stimulatory electrodes compared to the Quad and Pace
probes with 4 electrodes and 1 electrode, respectively. These
findings may be important in determining the design and clinical
efficacy of aortic baroreceptor stimulation probes for use in
human subjects.
The baroreceptor stimulation device physiologically activates
the efferent reflex reducing sympathetic activity and increase
parasympathetic out-flow. This leads to lowering of SBP, DBP,
MAP and pulse rate as was proven in this study.
Although the carotid stimulation has been used previously for
the treatment of resistant hypertension and heart failure there
is no data available comparing carotid and aorta stimulation
techniques (20–22).
The current study did not evaluate the effect of general
anesthesia on baroreceptor stimulation. In addition, significant
autonomic sympathetic activity may transiently overcome the
effects of aortic baroreceptor stimulation and the animals used
in this study were healthy and normotensive. A similar study
using conscious animals and animals with hypertension will be
required to determine whether or not the response to aortic
baroreceptor stimulation is comparable to that observed in
normotensive, anesthetized animals.
Limitations of this study are firstly that anesthetized and
normotensive animals were used. Future experiments in active
and hypertensive animals need to be done to prove the same
outcome/results. Secondly the hemodynamic effect of long-term
stimulation of aortic baroreceptor is not investigated. Future
studies in this regard are necessary to establish if the same blood
pressure lowering can be achieved.
A less invasive approach via mediastinoscopy is planned in
a vertebrate animal such as primates, is planned. The effect of
aortic baroreceptor stimulation on blood pressure in humans is
still unknown. This could only be investigated further if sufficient
data in animal models regarding safety and efficacy can be
confirmed.
Future application of this research might lead to an alternative
method to treat blood pressure in the resistant hypertensive
population where it is known that numerous drugs are
ineffective to reduce blood pressure to target values. In addition
hypertension treatment during pregnancy limits the drugs that
are available to treat blood pressure optimally. This non-
pharmacological method might provide an alternative way to
treat hypertension in future.
In conclusion, stimulation of aortic baroreceptors caused a
significant decrease in SBP, DBP MAP and pulse rate and may
represent a novel and alternative modality to treat systemic blood
pressure in human subjects with hypertension provided these
results in an animal model are repeatable in human trials.
The potential utility of this form of therapy may include
subgroups of patients with resistant hypertension or those who
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experience significant side effects from pharmacological therapy.
A new system for aortic arch baroreceptor stimulation that
involves an implant procedure is currently under research for
blood pressure lowering.
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